Oncology
96 articles
Summit, AstraZeneca and Daiichi Sankyo to test ivonescimab plus Datroway, starting with Phase III in 1L TNBC
- Summit, AstraZeneca and Daiichi Sankyo announced a clinical collaboration combining ivonescimab (PD-1xVEGF bispecific) with Datroway (datopotamab deruxtecan, a TROP2-directed ADC).
- It starts with a Phase III study in first-line triple-negative breast cancer, with plans to expand to other settings including lung cancer.
- The companies will share trial costs, and each retains development and commercial rights to its own drug.
Three companies, two assets, and no one gives up rights: this is a cost-sharing structure, not a licensing deal. For Summit, pairing ivonescimab with a validated TROP2 ADC borrows AstraZeneca and Daiichi's TNBC credibility and trial muscle. For the big partners, it is a cheap hedge on the PD-1xVEGF class. I would want to see the control arm and endpoints before judging how much it de-risks.
Summit partners with AstraZeneca and Daiichi; Eccogene earns $50M milestone ↗
Aryl alkyl ether CD73 inhibitor LB10 is orally active in a lung cancer model
- CD73 is the rate-limiting enzyme of the adenosine pathway and a tumor-immunosuppression target.
- An aryl alkyl ether series was designed; LB10 emerged as the most promising, potent in both biochemical and cell assays.
- Enzyme kinetics and co-crystallography confirmed competitive inhibition.
- LB10 had low cytotoxicity and good pharmacokinetics, and oral dosing curbed tumor growth in a syngeneic Lewis lung carcinoma model, alone or in combination.
Non-nucleotide CD73 inhibitors that stay orally bioavailable are the part I care about: most potent early chemotypes were AMP-like and carried the usual permeability and clearance baggage. A co-crystal confirming a competitive mode gives a clean starting point for SAR around the ether linker. I would want to see how it behaves against the soluble versus membrane-bound enzyme and in human-relevant adenosine readouts before getting excited.
Shutting down JNK signaling resensitizes KRAS G12D-resistant pancreatic cancer cells
- Pancreatic cancer cells that adapt to KRAS G12D inhibition can be pushed back toward sensitivity by suppressing the JNK pathway more completely.
- Selective covalent inhibitors of MAP2K4, MAP2K7, or both were used to probe how much JNK suppression is needed.
- Stronger JNK blockade disables the feedback loop that reactivates KRAS signaling in resistant cells.
- Inhibitor-sensitive cells gain no benefit, so the vulnerability is specific to the resistant state.
If this holds up, the interesting part is the logic: resistance to a KRAS G12D inhibitor runs through JNK feedback, so you hit the node that rewires the pathway, not KRAS again. Covalent engagement of MAP2K4 and MAP2K7 is a neat way to ask how deep the suppression must be, though kinase selectivity between the two will be the real SAR headache. Sparing sensitive cells is the encouraging bit; it's abstract-level so far.
DT-9081: Scaffold Hopping Delivers an Oral EP4 Antagonist That Has Cleared Phase I
- EP4 blockade is an immuno-oncology idea built on PGE2-driven immune suppression in tumors.
- Scaffold hopping gave a new chemical series with better activity and pharmacokinetics, and SAR work led to DT-9081.
- It combines potent antagonism, favorable ADME and a clean preclinical safety profile, and has completed a phase I monotherapy trial in solid cancers.
This paper is the full med-chem story behind a compound that already has human data, which is rarer and more useful than most 'discovery of' papers. EP4 is crowded, so the interesting part is how the new series differentiates on PK and safety against earlier antagonists. I'd read it for the scaffold-hop logic and watch whether phase I translates into combination activity with checkpoint blockade.
Aryl Sulfamates Get a Systematic SAR Look as Carbonic Anhydrase IX Binders
- Ortho- and meta-substituted aryl sulfamates were synthesized and profiled by thermal shift, enzyme inhibition and a live-cell competition assay against CA IX, the isozyme overexpressed in hypoxic solid tumors.
- The best compounds bound CA IX with very high affinity, and X-ray structures with several isozymes identified the groups driving affinity and selectivity.
- pH-dependent binding data indicate the deprotonated, negatively charged sulfamate nitrogen coordinates the active-site zinc.
CA inhibitors are dominated by sulfonamides, so a clean sulfamate SAR backed by crystal structures is useful chemotype diversification. Selectivity over the ubiquitous CA I and II is what sinks tumor-CA programs, and the co-crystals give a concrete handle on it. Live-cell competition data beat purely recombinant assays, but I'd want hypoxic-cell potency and physicochemical properties before calling these lead-like.
Structure-Affinity and Selectivity of Aryl-Sulfamates as Inhibitors of Carbonic Anhydrase IX ↗
AstraZeneca Takes a $2B Stake in Summit to Pair Ivonescimab with Its ADCs
- AstraZeneca is buying $2B of convertible preferred stock, giving it about 12% of Summit's common stock (about 10.6% fully diluted).
- The first combination pairs Summit's PD-1xVEGF bispecific ivonescimab with AstraZeneca's CLDN18.2-directed ADC in gastrointestinal cancers; a memorandum of understanding covers a broader program with more AstraZeneca ADCs.
This is AstraZeneca buying a seat rather than a pipeline: equity plus combination rights instead of an acquisition or license, keeping it close to a PD-1xVEGF class it doesn't own without paying for the asset outright. The bet is that ADC plus PD-1xVEGF combinations become a next oncology backbone, with AstraZeneca's ADC portfolio as the partner of choice. The broader MOU is non-binding, so definitive terms are the thing to watch.
AstraZeneca scales Summit's PD-1xVEGF strategy with $2B investment to fuel ADC combinations ↗
Genentech Pays $55M Upfront for Earendil’s AI-Built Oncology Bispecifics
- Genentech will pay Earendil Labs $55 million upfront, with up to about $1.445 billion in development, regulatory and sales milestones, plus tiered royalties.
- Earendil leads antibody discovery and early clinical work on pre-agreed target pairs using its AI antibody-generation platform; Genentech takes over global development and commercialization.
Roche is buying optionality on target combinations, not a single asset: a small upfront against a milestone-heavy tail is the classic platform structure, and it limits the downside if the AI-generated molecules disappoint. The signal is that big pharma still wants bispecific capacity in oncology after the PD-1×VEGF rush, and is willing to source it from AI-native shops.
Roche's Genentech inks $1.5B bispecific pact with fast-rising Earendil… ↗
Merck Licenses China-Origin KRAS G12D Inhibitor SPR2015 for $400M Upfront
- Merck & Co. entered an exclusive global license agreement with Shanghai-based SciBrunch Therapeutics for SPR2015, an investigational oral KRAS G12D molecular-glue inhibitor.
- SciBrunch will receive $400 million upfront, with total deal value up to $2.13 billion including milestone payments.
- The deal reflects a growing trend of U.S. pharma companies in-licensing China-originated oncology assets.
This plugs Merck's biggest KRAS gap: everyone's crowded into G12C, but G12D — more common in pancreatic and colorectal cancer — has stayed stubbornly undrugged with covalent chemistry. A molecular-glue approach, if it works, sidesteps that entirely. The modest 19% upfront-to-total ratio signals early-stage derisking, not a validated asset — expect Western rivals to scramble for the remaining China-origin G12D candidates.
Merck, Daiichi Sankyo Withdraw FDA Application for Ifinatamab Deruxtecan in Lung Cancer
- Merck & Co. and Daiichi Sankyo voluntarily withdrew their FDA BLA for ifinatamab deruxtecan, a B7-H3-targeted ADC, in previously treated ES-SCLC.
- FDA feedback indicated Phase 2 data didn't support accelerated approval, marking the alliance's second pullback for the drug after an earlier lung-toxicity-related clinical hold.
- The companies continue the Phase 3 IDeate-Lung02 confirmatory trial and other Phase 3 studies in prostate and esophageal cancer.
A second stumble for the same molecule is a real signal, but it's about ifinatamab deruxtecan's timeline, not the Merck-Daiichi deal's overall health — this alliance is bigger than one BLA. Withdrawing rather than fighting for a contested approval is the disciplined move, protecting IDeate-Lung02's confirmatory data package. But every added year gives rival B7-H3 ADC programs room to catch up.
Merck, Daiichi scrap FDA application for B7-H3 ADC in lung cancer ↗
NanoBRET Assay Validates p53 Y220C Ligand Engagement in Living Cells
- Researchers built a live-cell NanoBRET assay to test whether reported p53 Y220C ligands truly engage the mutant protein inside intact cells.
- The BRET-based readout gives a cell-based engagement ranking for known Y220C stabilizer/reactivator compounds, complementing prior biochemical binding data.
- Such cellular validation checks permeability and intracellular target occupancy, a key hit-to-lead checkpoint for this hard-to-drug p53 cavity mutant.
Compounds that light up beautifully in DSF or ITC routinely stall out crossing a membrane into that buried, polar cavity — a cell-based BRET ranking is built to catch precisely that failure mode before a Y220C hit gets pushed into SAR. I'd still want it cross-referenced against a functional readout like p21 induction or apoptosis, and benchmarked directly against rezatapopt's (PC14586) cellular engagement window before trusting the ranking over biochemical Kd.
NanoBRET Target Engagement Enables Validation of p53 Y220C Ligands in a Cellular Context ↗
New Dual-Acting Molecules Pair PARP Inhibition with Ferroptosis to Fight TNBC
- Medicinal chemists designed single small molecules combining PARP inhibition with GPX4 inhibition, pairing DNA-repair blockade with ferroptosis induction in one compound rather than as a drug combination.
- Structure-activity relationship work identified a new dual-acting chemotype optimized for potency against both targets.
- Lead compounds showed antitumor activity in triple-negative breast cancer models, supporting the dual-mechanism approach as a possible way to broaden PARP inhibitor efficacy.
Most TNBC is BRCA-wild-type, so PARP monotherapy has nowhere to go without synthetic lethality — pairing it with GPX4 inhibition to force ferroptosis is a real way around that, not just an add-on. The tougher ask is holding potency at two unrelated targets in one scaffold without MW/logP creeping past drug-like — if they pulled that off cleanly, it's more interesting than the biology.
Discovery of Dual PARP/GPX4 Inhibitors for the Treatment of Triple-Negative Breast Cancer ↗
Aminopyrazole Lead Optimization Yields Selective PLK4 Inhibitor EXEL-1855
- Exelixis researchers optimized an aminopyrazole hit series targeting PLK4, a kinase essential for centriole duplication, culminating in the advanced compound EXEL-1855.
- Structure-guided SAR and selectivity profiling addressed off-target kinase liabilities that had limited earlier aminopyrazole PLK4 inhibitors such as centrinone.
- In preclinical tumor models, EXEL-1855 showed strong antitumor activity, supporting its selection as a development candidate.
Selectivity was always the aminopyrazole scaffold's weak spot — centrinone's off-target kinase hits (PLK1/2/3, Aurora) made it a great chemical probe but a poor drug candidate. Getting EXEL-1855 to "development candidate" with a clean kinome profile is the real milestone here, not the potency number. PLK4's centrosome-duplication mechanism is also refreshingly uncrowded real estate next to the CDK/Aurora pileup.
AI Pocket-Based Design Yields a Potent STAT3 Inhibitor for Colorectal Cancer
- A pocket-conditioned, autoregressive generative AI model was used to design candidate molecules directly within the STAT3 binding pocket, rather than screening pre-existing compound libraries.
- This structure-based generative approach produced a potent small-molecule STAT3 inhibitor that advanced to biological evaluation.
- The inhibitor showed activity against colorectal cancer, where STAT3 hyperactivation is a recognized driver of tumor growth and survival.
STAT3's SH2 dimerization pocket is shallow and dynamic — the reason most inhibitor programs (niclosamide analogs, peptidomimetics) never reached clinic. Generating atoms directly inside that pocket geometry, rather than rescoring a static virtual library, is the real methodological jump here. Still, "potent" on paper means little until we see SH2 selectivity over STAT1/5 and a synthesizable route — that's where de novo hits usually stall.
A Smarter Sugar Anchor Sharpens a Phage-Based Cancer Vaccine
- Chemists built fluorinated Tn-antigen mimics using a tyrosine-linked GalNAc (Tyr-GalNAc) instead of the natural serine/threonine attachment, then conjugated them to bacteriophage Qβ virus-like particles.
- Qβ is a multivalent carrier platform known for driving strong antibody responses to small carbohydrate tumor antigens.
- The fluorinated Tyr-GalNAc-Qβ conjugates showed potent antitumor activity in preclinical models, adding to evidence that targeted fluorination can boost carbohydrate-antigen vaccine immunogenicity.
Tn's Achilles' heel has always been the native GalNAc-α-O-Ser/Thr linkage: glycosidase-labile and a weak, self-like hapten that struggles to break B-cell tolerance. Rerouting to a Tyr-aryl glycoside dodges the enzymes evolved for O-Ser/Thr GalNAc, and fluorination looks like classic conformational/electronic tuning to sharpen epitope recognition. Neither move touches the target — it's synthetic hapten engineering, with Qβ's ~180-copy multivalent display doing the real work of forcing an antibody response.
Lilly Strikes Up to $3.35B Discovery Deal with China's InnoCare
- Eli Lilly signed a discovery-stage collaboration and licensing deal with Beijing-based InnoCare Pharma worth up to $3.35 billion.
- Terms include up to $100 million upfront, up to $3.25 billion in milestones, and royalties, as InnoCare hunts compounds against up to five undisclosed targets.
- It marks Lilly's fourth China-biotech deal since early 2025, after Insilico Medicine, Innovent Biologics and Haisco.
Fourth China-sourced discovery deal for Lilly since early 2025 — this is deliberate strategy, not opportunism: outsourcing early-target risk to lower-cost Chinese biotech engines. The $100M upfront against $3.35B total (~3%) is a cheap option on unproven targets, not a derisked buy. China's shifting from manufacturing base to discovery pipeline for Big Pharma.
In another China pact, Lilly makes a deal with InnoCare worth up to $3.35B ↗
GSK Doubles Down on China-Sourced ADCs After Hansoh Deal Delivers Phase 3 Win
- In 2023, GSK paid about $270 million upfront for ex-China rights to two Hansoh Pharma antibody-drug conjugates targeting B7-H3 and B7-H4.
- The B7-H3 candidate has since posted an 18.5-month median overall-survival benefit in relapsed small-cell lung cancer, plus a progression-free-survival win in osteosarcoma.
- GSK plans to push the B7-H4 asset into five additional Phase 3 trials, reinforcing a dual in-house/China-sourced oncology pipeline strategy.
The $270M upfront now looks like a steal — a Phase 3 survival win in SCLC plus a PFS hit in osteosarcoma would command a far richer price today, which is exactly why AstraZeneca, Merck and Pfizer scrambled to strike their own China ADC deals. Five more B7-H4 Phase 3s isn't optionality — it's GSK committing real capital to a China-sourced pipeline, not hedging it.
GSK aiming to 'balance West and East' after Hansoh deal success showed China's potential ↗
CRBN-Based Degrader Removes PTP1B and TCPTP to Reawaken Anti-Tumor T Cells
- Scientists converted an F2Pmp-based dual PTP1B/TCPTP inhibitor into a CRBN-recruiting bifunctional degrader, named X1.
- X1 shows improved potency, selectivity, and plasma exposure after intraperitoneal dosing versus earlier tools.
- Degrading both phosphatases boosts TCR signaling in T cells and IFNγ-driven JAK/STAT1 signaling in tumor cells, raising MHC-I antigen presentation.
- In a mouse tumor model, X1 alone or with anti-PD-1 increased T cell infiltration/activation and drove robust anti-tumor efficacy.
F2Pmp warheads are notoriously charged and permeability-poor, so seeing real plasma exposure after IP dosing of a CRBN degrader built on one is the actual win here — event-driven pharmacology bailing out a classically undruggable phosphotyrosine mimetic. Also curious whether ternary-complex formation buys any PTP1B/TCPTP discrimination beyond what the near-identical catalytic sites let the warhead alone achieve.
Discovery and Characterization of a Cereblon-Based Degrader for PTP1B and TCPTP ↗
Imidazole Scaffold Swap Delivers Selective, Oral CDK2 Inhibitor INCB127443
- An earlier pyrazole-based CDK2 inhibitor scaffold was computationally redesigned around an imidazole core to improve selectivity over CDK1.
- The new chemotype was optimized simultaneously for potency, CDK1/CDK2 selectivity, and physicochemical properties.
- This work yielded INCB127443, an orally bioavailable candidate with favorable CDK1 selectivity and a flat pharmacokinetic profile enabling sustained in vivo target coverage.
Swapping pyrazole for imidazole to fix CDK1 selectivity is a single-atom-position bet—when it works, it usually means the selectivity handle is a subtle H-bond vector difference in the near-identical ATP pockets, not a size mismatch, which is the harder kind to exploit on purpose. Imidazole is cheap, well-trodden SAR territory, and the flat PK is the real prize for sustained target coverage.
Discovery of INCB127443: A Potent and Orally Available Inhibitor of Cyclin-Dependent Kinase 2 ↗
Chemists Report New Allosteric SHP2 Inhibitors Built on an Azaindole Scaffold
- SHP2 is a cytosolic protein tyrosine phosphatase implicated in oncogenic RTK and immune checkpoint signaling, making it a closely watched cancer/immuno-oncology target.
- Earlier allosteric SHP2 inhibitors have reached clinical trials but can face resistance mutations or PK limitations, motivating further chemotype exploration.
- This preprint reports a new series of N-aryl-1H-azaindole-derived allosteric SHP2 inhibitors, shifting away from orthosteric (active-site) inhibition approaches.
That shallow, conserved catalytic pocket is exactly why orthosteric SHP2 programs never went anywhere in my hands—no surprise this moves allosteric. But the irony's real: clinical allosteric inhibitors like TNO155 already picked up resistance mutations right in that allosteric tunnel, so a new chemotype needs to show it escapes those hotspots, not just re-occupy the same pocket with a different scaffold.
Novel TRPM7 Inhibitors Curb Breast Cancer Growth and Invasion in Preclinical Models
- Building on the TRPM7 blocker NS8593, researchers created a set of 2-aminobenzimidazole analogues and identified two standout leads, SDUY212 and SDUY225, validated by electrophysiological recordings.
- Both compounds slowed growth, migration and invasion in MCF-7 and MDA-MB-231 breast cancer cells and triggered apoptosis and cell-cycle arrest; SDUY212 also shrank tumors in xenograft-bearing mice.
- The anti-invasive effect appeared linked to reduced EGF-triggered STAT3 activation downstream of TRPM7.
Actually running electrophysiology on the leads, not just IC50s from a fluorescence assay, is what makes me trust this series — ion channel hits die in droves from off-target and assay artifacts. Still, I'd want a TRPM6/TRPM8 selectivity panel before calling SDUY212 a real chemical probe; TRPM7 has essentially none, and the 2-aminobenzimidazole scaffold looks synthetically forgiving enough to actually chase that SAR.
Nvidia-Backed AI Drug Discovery Startup Iambic Files for Nasdaq IPO
- Iambic Therapeutics filed for a Nasdaq IPO under ticker IAM, seeking up to $100 million.
- The AI-native drug discovery company combines machine-learning models with automated wet-lab chemistry, backed by Nvidia and Coatue.
- Its lead program, an oral HER2 inhibitor called IAM1363, is in early-stage trials for HER2-altered solid tumors.
- 2025 revenue was about $9 million, while net loss widened to roughly $77 million.
Iambic's IPO is really a referendum on whether public markets still believe in the AI-native drug discovery thesis after Recursion's and BenevolentAI's rocky rides. A $100M raise against a $77M net loss and just $9M in revenue is thin, and Nvidia's and Coatue's names on the cap table are doing more of the selling here than IAM1363's early data.
Nvidia-backed AI biotech Iambic Therapeutics files for IPO ↗
Telix Bets $1.65B on Radiopharma Rival to Take On Novartis
- Telix Pharmaceuticals agreed to acquire Germany's ITM for $1.65 billion upfront, plus up to $700 million in milestones tied to its lead radiopharmaceutical candidate.
- The deal pairs Telix's diagnostics business with ITM's lutetium-177 supply chain, setting up direct competition with Novartis' Lutathera in neuroendocrine cancer.
- Telix will assume some of ITM's debt, and the companies expect to close the transaction by year-end 2026.
At $1.65B upfront plus $700M in milestones — and assumed debt pushing the all-in cost near $2.4B — Telix is essentially replicating Novartis's own AAA/Endocyte playbook: buy the isotope supply chain, not just the molecule. Pairing ITM's Lu-177 manufacturing with Telix's diagnostics scale is the only realistic way a challenger dents Lutathera's neuroendocrine near-monopoly.
Telix beams into Novartis' territory with $1.6B ITM acquisition ↗
Next-Gen AOH1996 Analogs Sharpen the Attack on Cancer's PCNA Isoform
- Second-generation analogs of the first-in-class caPCNA-selective inhibitor AOH1996, built by systematically modifying each of its four pharmacophoric regions.
- Explored substituent changes, bioisosteric swaps, linker adjustments, and scaffold hopping to improve on the parent compound.
- Lead analogs showed markedly improved cancer cell potency and better liver microsomal metabolic stability than AOH1996.
- Compounds were profiled across multiple cancer cell lines, including neuroblastoma and breast/colorectal cancer models.
Four pharmacophoric regions systematically walked — substituents, bioisosteres, linkers, and a scaffold hop — is a proper second-generation SAR campaign, not a token tweak. Pairing better cancer-cell potency with improved microsomal stability is what actually matters for a caPCNA-interaction disruptor, since these shallow, protein-interface-driven pockets are usually the first thing to fall apart metabolically.
Second-Generation AOH1996 Analogues with Enhanced Pharmacological Properties for Targeting PCNA ↗
Degrading CK1δ to Disarm 'Undruggable' NRAS-Mutant Melanoma
- Targets CK1δ, an upstream kinase that stabilizes oncogenic NRAS mutant protein, as an indirect strategy against NRAS-driven melanoma.
- Reports discovery of compound 8u, a selective small-molecule degrader rather than a simple catalytic inhibitor.
- The degrader approach achieves high selectivity for CK1δ over closely related CK1 isoforms, addressing a limitation of earlier inhibitors.
- Treatment destabilizes mutant NRAS protein and suppresses oncogenic signaling in melanoma models.
Smarter to go after 'undruggable' mutant NRAS through the kinase that stabilizes it than to keep chasing the mutant protein directly, and a degrader — not a catalytic inhibitor — is what finally buys the CK1 paralog selectivity this target class has chronically lacked. Compound 8u reads like a real template, not just a tool compound to prove the hypothesis.
Telix Acquires Radioisotope Maker ITM in Deal Worth Up to $2.35B After FDA Setback
- Telix Pharmaceuticals (Australia) agreed to acquire privately held ITM Isotope Technologies Munich (Germany) for about $1.65 billion upfront, largely in Telix shares plus assumed ITM debt, with up to $700 million more in milestones for a potential $2.35 billion total.
- The deal follows the FDA's surprise rejection of ITM's lead drug ITM-11, a GEP-NET radiopharmaceutical meant to rival Novartis's Lutathera, over manufacturing issues at a third-party facility, not safety or efficacy concerns.
- ITM also brings a profitable, commercial-scale isotope production and supply business, strengthening Telix's control over its radiopharmaceutical isotope supply chain.
- Post-close, Telix shareholders will hold about 76.3% of the combined firm, with ITM shareholders holding about 23.7%.
- Combined pro forma 2026 revenue is projected above $1.3 billion, with positive operating earnings expected from 2027.
This is a supply-chain acquisition wearing a pipeline-expansion label. Telix just watched ITM's lead asset get rejected over third-party manufacturing — not efficacy — so buying the isotope producer outright is the cleanest way to internalize that risk rather than keep depending on external CDMOs. Expect Telix to lean hard on ITM's commercial-scale production capacity to de-bottleneck its own growing radiotherapeutic franchise. The structure tells the real story: roughly $1.65B mostly in stock plus assumed debt, with $700M gated behind milestones, is classic risk-sharing for an asset whose flagship product just got an unexpected FDA no. Telix isn't paying cash for certainty it doesn't have yet. Strategically, this vaults Telix into direct, vertically integrated competition with Novartis's Lutathera franchise, and signals radiopharma is entering a consolidation phase where isotope supply, not just molecules, is the scarce asset worth owning.
Radiopharma companies merge after one receives surprise FDA rejection ↗
Second-Generation AOH1996 Analogues Show Improved Potency Against Cancer-Associated PCNA
- PCNA supports at least 11 cellular pathways in DNA replication and repair; tumor cells express a distinct acidic isoform (caPCNA) not found in normal cells, creating a potential cancer-selective drug target.
- AOH1996 is City of Hope's first-in-class small-molecule PCNA inhibitor, which binds the PIP-box pocket to disrupt caPCNA protein interactions and selectively kill malignant cells.
- This paper describes second-generation AOH1996 analogues built through systematic structure-activity relationship work (substituent changes, bioisosteric replacement, linker and heteroatom modification, scaffold hopping) across all four pharmacophore regions.
- Lead analogues showed improved cellular potency against multiple cancer cell lines and better liver microsomal stability than first-generation AOH1996, supporting further lead optimization of this PCNA-targeted chemotype.
- The real headline isn't the potency bump — it's that the PIP-box pocket, a shallow PPI interface people wrote off as undruggable, actually supports systematic SAR across four independent pharmacophore regions. That's a proper chemotype, not a lucky HTS hit. - Getting better cellular potency AND better microsomal stability out of substituent/bioisostere/linker/scaffold-hop work is the signal I want at this stage — potency alone would leave me wondering if you'd just traded one metabolic liability for another. - "Selective for caPCNA" is a claim I'll hold loosely until I see a real therapeutic index — normal-cell counterscreens and in vivo tox, not just cancer-line IC50s. The acidic-isoform story is attractive but easy to oversell. - Still, beating first-gen AOH1996 on both axes is the right trajectory for a second-gen PPI series.
Second-Generation AOH1996 Analogues with Enhanced Pharmacological Properties for Targeting PCNA ↗
New CK1δ-Targeting Degraders Curb NRAS-Mutant Melanoma Growth
- Building on prior work identifying CK1δ as an upstream stabilizer of oncogenic NRAS, the team developed small-molecule degraders that trigger CK1δ's proteasomal breakdown.
- Chemical optimization focused on achieving selectivity for CK1δ over its close paralogs CK1α and CK1ε, which share highly similar kinase domains.
- Iterative structure-activity relationship analysis across a synthesized compound series balanced degradation potency, isoform selectivity, and cellular activity.
- Degrading CK1δ removed its support for oncogenic NRAS protein stability, lowering NRAS levels and dampening downstream signaling in melanoma cells.
- In NRAS-mutant melanoma cell models, the optimized degraders suppressed proliferation, positioning CK1δ degradation as a potential strategy for an otherwise hard-to-drug oncogenic driver.
CK1δ/α/ε selectivity is the real fight here — those kinase domains are similar enough that classic ATP-competitive chemistry rarely holds up cleanly; if they're threading that needle with a degrader, ternary-complex geometry, not just binary affinity, is probably doing the selectivity work, which is the whole pitch for going bifunctional over yet another inhibitor. Smart use of event-driven pharmacology to reach something genuinely undruggable — NRAS has no covalent handle like G12C, so knocking down an upstream stabilizer is a legitimate end-run, not a gimmick. Still want to see the actual chemotype and E3 handle before getting excited — 'synthesized series, iterative SAR' tells me nothing about scaffold novelty or synthetic cost, and degrading a kinase with this many substrates makes me nervous about toxicity beyond the CK1α story. If selectivity and PK hold up in vivo, this is a template worth stealing for other 'stabilizer' targets propping up undruggable oncoproteins.
Dual PARP-1/CK2α Inhibitors Aim Beyond HRD-Restricted Tumors
- Researchers designed a new class of small molecules built on a benzothieno[3,2-d]pyrimidin-4(1H)-one scaffold that simultaneously inhibits PARP-1 and casein kinase 2 alpha (CK2α).
- PARP-1 inhibitors typically benefit only tumors with homologous recombination deficiency (HRD); pairing PARP-1 blockade with CK2α inhibition, a kinase linked to DNA damage response and cell survival signaling, is proposed to extend efficacy to HRD-proficient tumors and limit metastatic spread.
- Structure-activity relationship exploration identified substituents on the tricyclic core that support potent, balanced binding at both targets.
- In cellular and tumor models, the dual inhibitors reportedly show antiproliferative and anti-metastatic activity independent of HRD status, supporting dual-target inhibition as a route beyond BRCA-mutant-restricted use.
Holding balanced dual-target SAR on one scaffold is the real difficulty here, not the headline claim — PARP-1's nicotinamide pocket and CK2α's ATP site are shaped nothing alike, so a substituent you add to hold potency at one target can quietly tank the other. I'd want the full SAR table, not just the lead actives, before believing that balance survives further optimization. The real payoff isn't PARP-1 potency itself, it's escaping the BRCA/HRD ceiling — another single-target PARP inhibitor chasing olaparib's lane is a hard sell, but HRD-independent activity actually opens new patient populations. The tricyclic benzothienopyrimidinone core gives usable vectors for dual substitution, though fusing two pharmacophores tends to inflate MW and logP fast. Next data I need: kinome-wide selectivity beyond CK2α, in vivo therapeutic window, and whether the anti-metastatic signal holds up against a PARP-1-only comparator.
GSK licenses HUTCHMED's first-in-class KRAS-EGFR conjugate HMPL-A830 in deal worth up to $1.3B
- HUTCHMED and a GSK subsidiary signed an exclusive development and license agreement for HMPL-A830, described as a first-in-class KRAS-EGFR Antibody-Targeted Therapy Conjugate (ATTC).
- HMPL-A830 pairs a highly selective, potent small-molecule KRAS inhibitor payload with an anti-EGFR antibody, delivering the inhibitor selectively to EGFR-expressing tumor cells while also blocking EGFR signaling.
- GSK gains worldwide development and commercialization rights excluding Mainland China, Hong Kong, Macau and Taiwan, which HUTCHMED retains.
- Deal terms: $110 million upfront, up to $1.295 billion in additional development, regulatory and commercial milestone payments, plus tiered royalties on net sales.
- HUTCHMED will conduct the global Phase 1 program, expected to start in H2 2026, after which GSK takes over subsequent clinical development and commercialization.
- Initial clinical development will focus on colorectal, pancreatic and lung cancers.
Another Western major fills its oncology pipeline via China-origination rather than in-house discovery — GSK joins a fast-growing queue of ADC/conjugate deals mining HUTCHMED's pipeline for de-risked-but-early assets. The math is telling: $110M upfront against a $1.295B ceiling is roughly 8.5% at signing — real conviction, heavily hedged, standard for a preclinical/Phase 1 asset where GSK is paying mostly for optionality until clinical data lands. The ATTC design — a small-molecule KRAS payload riding an EGFR antibody — is a genuinely differentiated angle in an overcrowded KRAS field, avoiding classic cytotoxic-ADC toxicity while adding tumor-selective targeting. And HUTCHMED keeping Greater China rights again signals its now-familiar playbook: license out ex-China, retain commercial control at home.
GSK to license Hutchmed's KRAS-EGFR cancer drug for $110M upfront ↗
BioNTech, Genentech Terminate Phase 2 Trial of mRNA Cancer Vaccine Autogene Cevumeran in Colorectal Cancer
- Autogene cevumeran is an individualized, tumor-specific neoantigen mRNA vaccine designed to trigger a T-cell response against a patient's unique tumor mutations.
- Phase 2 trial BNT122-01, run with Genentech, evaluated it as adjuvant monotherapy versus watchful waiting in ctDNA-positive patients with surgically resected Stage II (high-risk) or Stage III colorectal cancer, targeting roughly 327 enrollees with disease-free survival as the primary endpoint.
- BioNTech and Genentech terminated the trial on August 28, 2026, after an independent Data Safety Monitoring Board (DSMB) identified a numerical overall-survival imbalance disfavoring the vaccine arm and concluded continuation was unlikely to change the efficacy outcome; no new safety signals were found.
- A separate, unaffected Phase 2 trial (Imcode003) continues to evaluate autogene cevumeran combined with checkpoint inhibition and chemotherapy in adjuvant pancreatic ductal adenocarcinoma.
- BioNTech shares fell as much as 8% on the news.
An OS imbalance with no new safety signal is a different failure mode than a safety-driven halt — it indicts adjuvant monotherapy in CRC, not necessarily neoantigen mRNA vaccines as a modality. That distinction matters competitively: Moderna/Merck's V940 (INT) has paired its individualized vaccine with pembrolizumab from the outset rather than testing it solo against watchful waiting, and BioNTech's own still-running pancreatic trial (Imcode003) uses that same vaccine-plus-checkpoint-inhibitor-plus-chemo architecture. So the part of the platform that just failed is arguably its least mechanistically ambitious use case. The 8% single-day drop on one Phase 2 readout, though, is the bigger tell — it shows how much of BioNTech's valuation still rests on individualized-vaccine optionality rather than de-risked, validated pipeline.
BioNTech, Genentech terminate Phase 2 of personalized mRNA cancer vaccine ↗